Resource > Application notes >
Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury
Filed under: DILI, Disease modeling, Immune-medicated toxicity, NAFLD/NASH, and Safety toxicology
Kostrzewski et al
NAFLD is a spectrum of pathologies ranging from benign hepatic steatosis through to non-alcoholic steatohepatitis (NASH), which can ultimately lead to cirrhosis and liver cancer. There are currently no FDA approved drugs for the treatment of NAFLD/NASH and there is a clear requirement for better models to understand this disease.